跳至主要内容
临床试验/EUCTR2010-023070-40-GB
EUCTR2010-023070-40-GB进行中(未招募)不适用

An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - paradigm™3

ovo Nordisk A/S0 个研究点目标入组 16 人开始时间: 2011年1月7日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Patients with haemophilia B, aged 13-70 years and with a FIX activity of =2%.
  • Male patients with moderately severe or severe congenital haemophilia B with a FIX activity =2% according to medical records
  • History of at least 150 exposure days to other FIX products
  • Scheduled major surgery
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR interviews
  • Current FIX inhibitors =0.6 BU (central laboratory)
  • Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
  • ALT >3 times the upper limit of normal reference ranges at screening (central laboratory)
  • Immune modulating or chemotherapeutic medication

研究者

相似试验